Publications (96) VICENTE DAMIÁN ESCUDERO VILAPLANA publications

filter_list

2025

  1. Empowerment among breast cancer survivors using an online peer support community

    Supportive Care in Cancer, Vol. 33, Núm. 1

  2. ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling

    Bone Marrow Transplantation, Vol. 60, Núm. 10, pp. 1351-1360

  3. Monoclonal antibodies in severe asthma: outcomes from real-world data

    Frontiers in Medicine, Vol. 12

  4. Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: Real-World Experience at Hospitals in Spain

    Targeted Oncology, Vol. 20, Núm. 2, pp. 319-327

2024

  1. Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors

    European Journal of Hospital Pharmacy, Vol. 31, Núm. 5, pp. 409-415

  2. Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study

    Farmacia Hospitalaria, Vol. 48, Núm. 6, pp. 265-271

  3. Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient

    Journal of Oncology Pharmacy Practice, Vol. 30, Núm. 7, pp. 1268-1273

  4. The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD)

    Orphanet Journal of Rare Diseases, Vol. 19, Núm. 1

  5. Validation of a Questionnaire to Assess the Usability of and User Experience with Mobile Health Applications

    Healthcare (Switzerland), Vol. 12, Núm. 23

  6. [Translated article] Development and consensus of a dashboard model to evaluate research activity in Spanish Hospital Pharmacy Services

    Farmacia Hospitalaria, Vol. 48, pp. TS28-TS34

2023

  1. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  2. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

    Journal of medical economics, Vol. 26, Núm. 1, pp. 445-453

  3. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

    BMC Pulmonary Medicine, Vol. 23, Núm. 1

  4. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

  5. Possible heart failure caused by osimertinib in a lung cancer patient

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 1015-1020

2022

  1. A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

    Frontiers in Oncology, Vol. 12

  2. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital

    Frontiers in Public Health, Vol. 10

  3. Análisis coste-utilidad de venetoclax en combinación con obinutuzumab como tratamiento de primera línea de la leucemia linfocítica crónica en España

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 3, pp. 121-132

  4. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer

    Frontiers in Oncology, Vol. 12

  5. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13